Navigation Links
News briefs: May issue of the journal Chest
Date:5/4/2008

LATEST REVIEW SUGGESTS LABAs ARE SAFE AND EFFECTIVE FOR COPD

Previous research has linked the use of long-acting β2-agonists (LABA) to increased risk for adverse events or respiratory-related death in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD); however, a recent article shows this may not be the case. In a new metaanalysis, researchers from Spain, Argentina, and Uruguay reviewed the results of 27 randomized controlled clinical trials that met the following criteria: (1) study patients were over the age of 35 with stable COPD; (2) intervention included inhaled LABAs vs placebo, inhaled ipratropium bromide, or inhaled tiotropium; (3) studies were of at least 4 weeks duration; and (4) primary outcomes included severe exacerbations, all-cause mortality, and respiratory-related death. The review found that compared with placebo, LABAs reduced severe exacerbations by 21%, and patients given LABAs did not differ in all-cause or respiratory-related mortality. The review also found that LABA treatment was associated with significantly more severe COPD exacerbations compared with tiotropium. This study is published in the May issue of the journal CHEST.

ARDS MORTALITY RATES DECLINING

New research shows that, over the last decade, mortality rates for patients with acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) have steadily declined. In a metaanalysis, Belgian researchers reviewed 72 studies published between 1994 and 2006 that reported mortality rates for patients with ARDS or ALI. Mortality rates ranged from 15 to 72%, with the overall pooled mortality rate being 43%. Further analysis showed a significant decrease in overall mortality rates of approximately 1.1% per year over the decade analyzed. The decrease in mortality was more pronounced for hospital mortality than for mortality in the ICU. Researchers speculate that the decline in mortality may be the result of improvements in the treatment of patients with ARDS/ALI. This study is published in the May issue of the journal CHEST.

SMOKING PATTERN LINKED TO RARE PNEUMONIA

Acute eosinophilic pneumonia (AEP), a rare lung condition, may be associated with recent changes in smoking patterns. In a new study, Japanese researchers reviewed the smoking history and current smoking habits of 33 patients with AEP. All but one patient (97%) were current smokers. Alterations in smoking habits, such as initiating the smoking habit or increasing the number of cigarettes smoked, were seen in 87.9% of patients. Furthermore, a cigarette smoke provocation test was performed in nine patients, and all tested positive. Data suggest that cigarette smoking, particularly changes in smoking habits, is a possible AEP etiologic factor. This study is published in the May issue of the journal CHEST.


'/>"/>

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
Source:Eurekalert

Related medicine news :

1. UPDATE: Retirement Living TV Partners With Maryland Public Television to Address the Issue of Healthcare in America Through Its Series Healthcare 08: Search for Solutions
2. Lupus Organizations Issue International Call-to-Action to Combat Disease Affecting Five Million People
3. Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009
4. American Lung Association Issues State of the Air Report: First City Outside California (Pittsburgh) Tops One of the Most-Polluted Lists
5. Retirement Living TV Partners with Maryland Public Television to Address the Issue of Healthcare in America Through Its Series Healthcare 08: Search for Solutions
6. Patient Safety Authority Issues Annual Report for 2007
7. Three Million Californians Say Yes! to Organ and Tissue Donation
8. Congressional Organ and Tissue Donation Awareness Caucus Hosted Congressional Staff Meeting on April 29 to Spread the Truth About Organ Donation
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc.
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc.
11. Prominent Advocate on HIV/AIDS Issues Joins Altarum Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
(Date:6/24/2016)... ... 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The ... members that have been wounded in battle and their families. Venture Construction Group is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery ... Arizona pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic ... , Dr. Olson says the decision to support the pageant in an ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based ... however, are unsure how to move forward, given the need to sustain current ... forward tailored to an organization’s specific needs. , PYA Principal Martie Ross states, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: